Evidence map›Paper›PMID 35164699›Full record

Observational studyBMC infectious diseases2022

Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort.

Arthur H van Stigt, Katrien Oude Rengerink, Kitty W M Bloemenkamp, Wouter de Waal, Sabine M P J Prevaes, Thuy-My Le, Femke van Wijk, Maaike Nederend, Anneke H Hellinga, Christianne S Lammers and 11 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Arthur H van StigtCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Katrien Oude RengerinkDepartment of Biostatistics and Research Support, Clinical Trial Methodology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Kitty W M BloemenkampDepartment of Gynaecology and Obstetrics, University Medical Center Utrecht, Utrecht, The Netherlands.
Wouter de WaalDepartment of Pediatrics, Diakonessenhuis, Utrecht, The Netherlands.
Sabine M P J PrevaesDepartment of Pediatric Pulmonology and Allergology, Wilhelmina Children's Hospital/University Medical Center, Utrecht University, Utrecht, The Netherlands.
Thuy-My LeDepartment of Dermatology/Allergology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
Femke van WijkCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Maaike NederendCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Anneke H HellingaCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Christianne S LammersCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Gerco den HartogCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Martijn J C van HerwijnenDepartment of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Johan GarssenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Léon M J KnippelsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Lilly M VerhagenDepartment of Paediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands.
Caroline G M de TheijeDepartment of Neonatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
Alejandro Lopez-RinconDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Jeanette H W LeusenCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Belinda Van't LandCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
Louis BontCenter for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. L.Bont@umcutrecht.nl.
PRIMA Initiative Group
University Medical Center Utrecht · NLUtrecht University · NLDiakonessenhuis hospital · NLNational Institute for Public Health and the Environment · NLWilhelmina Children's Hospital · NL

Funding

Nutricia Research Foundation 20187710
6 · The paper itself

Abstract

backgroundMany studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the "Protecting against Respiratory tract lnfections through human Milk Analysis" (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life.

methodsFor the PRIMA human milk cohort we aim to recruit 1000 mother-child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. DISCUSSION: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.

Indexed as

HypersensitivityRespiratory Tract InfectionsBirth CohortBreast FeedingFemaleHumansInfantInfant, NewbornMilk, HumanProspective StudiesAllergiesAntibodiesBiobankBreastfeedingExtracellular vesiclesHuman milkHuman milk oligosaccharidesImmune developmentRespiratory tract infectionsT cells

Identifiers

PMID35164699
PMCPMC8842741
OpenAlexW4213012256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.